Respiratory syncytial virus: desperately seeking solutions
Prescriber
; 34(4):23-26, 2023.
Artículo
en Inglés
| EMBASE | ID: covidwho-20236237
ABSTRACT
Respiratory syncytial virus (RSV) infection remains a major public health problem, especially in younger children and the elderly. But several monoclonal antibodies, antivirals and vaccines, either recently launched or in development, offer new hope for RSV prevention and treatment.Copyright © 2023 Wiley Interface Ltd.
antiviral therapy; article; asthma; bronchiolitis; common cold; coronavirus disease 2019; coughing; fever; hand washing; health service; hospital admission; hospitalization; hospitalization cost; human; Human respiratory syncytial virus; immunization; influenza; intensive care; loss of appetite; lower respiratory tract infection; lung dysplasia; malaise; meta analysis (topic); nonhuman; pneumococcal infection; pneumococcal pneumonia; pneumonia; respiratory syncytial virus infection/dt [Drug Therapy]; rhinorrhea; social distancing; sore throat; nirsevimab/dt [Drug Therapy]; palivizumab/dt [Drug Therapy]; respiratory syncytial virus vaccine/dt [Drug Therapy]; ribavirin/dt [Drug Therapy]
Texto completo:
Disponible
Colección:
Bases de datos de organismos internacionales
Base de datos:
EMBASE
Tópicos:
Vacunas
Idioma:
Inglés
Revista:
Prescriber
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS